Editorial from The New England Journal of Medicine — PARAGON – HF — Why We Do Randomized, Controlled Clinical Trials, 11/18/2020 · The PARAGON – HF (ClinicalTrials.gov number, NCT01920711) investigated HF subjects class II to IV HF , ejection fraction of 45% or higher, elevated level of natriuretic peptides, and structural heart disease to receive sacubitril–valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or valsartan (target dose, 160 mg …
8/28/2019 · In patients with heart failure with preserved ejection fraction, use of the angiotensin receptor-neprilysin inhibitor sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes compared with valsartan alone, according to findings from the PARAGON – HF trial presented Sept. 1 at ESC Congress.
9/1/2019 · PARAGON – HF was designed to test the hypothesis that sacubitril/valsartan would improve outcomes in HFpEF. A total of 4,822 patients were randomly assigned to sacubitril/valsartan or valsartan. The comparator was valsartan because most HFpEF patients already take a renin-angiotensin system inhibitor. Patients were required to have signs and …
9/1/2019 · Editorial PARAGON – HF — Why We Do Randomized, Controlled Clinical Trials C.M. O’Connor and C. deFilippi Perspective Medical Deferred Action — Living on Borrowed Time L. Ganapathi and Others, 8/30/2019 · Editorial : O’Connor CM, deFilippi C. PARAGON – HF — Why We Do Randomized, Controlled Clinical Trials. N Engl J Med 2019381:1675-6. Presented by Dr. Scott Solomon at the European Society of Cardiology Congress, Paris, France, September 1, 2019. …
9/1/2019 · The way that I interpret the [ PARAGON – HF ] … Cardiology Today Editorial Board Member. Detroit Medical Center. Disclosures: Pina reports she is on the steering committee for PROVE- HF.
9/1/2019 · PARAGON – HF randomly assigned 4822 patients with HFpEF, which it defined as HF with an ejection fraction of at least 45%, and in NYHA class II.
7/29/2019 · Chalk up another flop in heart failure with preserved ejection fraction (HFpEF), this time for Novartis’s Entresto. The company had tried to avoid other groups’ misfortunes in this tricky indication by experimenting with a novel primary endpoint in the Paragon – HF trial, but in the end this came to naught.. Novartis still seems to hold out hope for Entresto in this use, with the.
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction Insights From PARAGON – HF . John J.V. McMurray, Alice M. Jackson, Carolyn S.P. Lam, Margaret M. Redfield, Inder S. Anand, Junbo Ge, Marty P. Lefkowitz, Aldo P. Maggioni, Felipe Martinez, Milton Packer,
